Science

Mar 5, 2025, 11:23

Plasma ctDNA Kinetics Predicts Therapy Response in Advanced NSCLC – International Society of Liquid Biopsy

International Society of Liquid Biopsy shared an article by Luís F Leite da Silva, et al. on X:

“Plasma ctDNA Kinetics Predicts Therapy Response in Advanced NSCLC.

Key Findings from a Systematic Review & Meta-Analysis:

ctDNA clearance/decrease strongly correlates with improved PFS & OS in NSCLC patients.
HR for PFS: 0.32 (68% lower risk of progression with ctDNA clearance).
HR for OS: 0.31 (69% lower risk of death with ctDNA reduction).
Benefits seen across targeted therapy (TT) & immune checkpoint blockade (ICB).
Tumor-informed assays showed a stronger predictive value vs. tumor-agnostic assays.

Longitudinal ctDNA monitoring can revolutionize personalized NSCLC treatment decisions!

Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis.

Authors: Luís F Leite da Silva, et al.

Plasma ctDNA Kinetics Predicts Therapy Response in Advanced NSCLC - International Society of Liquid Biopsy

cancer fight against cancer Global fight against cancer Immune checkpoint blockade International Society of Liquid Biopsy ISLB Luís F Leite da Silva non small cell lung cancer NSCLC OncoDaily Oncology plasma ctDNA targeted therapy

OncoBillionaires of 2025: The Titans Behind the Cancer Revolution

Val Kilmer Dies at 65: The Actor Who Fought Throat Cancer and Inspired Generations

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer